| Document |
Document Title |
|
WO/2007/034909 |
Disclosed is a (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative which is useful as an intermediate for a pharmaceutical. A (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative or a salt thereof can be produced by a process compri...
|
|
WO/2007/032362 |
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as...
|
|
WO/2007/027599 |
This invention provides compounds of Formula (I) having the structure where R1, R2, R3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (I...
|
|
WO/2007/015412 |
Disclosed is an organic electroluminescent device (organic EL device) of simple structure which is improved in luminous efficiency and sufficiently secured in driving stability. Also disclosed is a heterocyclic compound used for such an ...
|
|
WO/2007/013201 |
A zinc fluorescent probe that excels in water solubility, enabling observing with high sensitivity of any change of intracellular zinc ion level ratiometrically with the use of a single excited wavelength; a process for producing the sam...
|
|
WO/2007/010514 |
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...
|
|
WO/2007/010514 |
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...
|
|
WO/2007/000383 |
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.
|
|
WO/2006/134955 |
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...
|
|
WO/2006/129036 |
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...
|
|
WO/2006/129736 |
It is intended to provide an industrially advantageous process for producing a cyclic ester, an industrially advantageous process for producing a cyclic oxyester which is a raw material of poly(hydroxyalkyloxyacetic acid ester), and an i...
|
|
WO/2006/129036 |
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...
|
|
WO/2006/127235 |
Clarified polyolefins such as polypropylene are used widely to make polymer articles, containers, and the like. Such articles may be manufactured by the injection of molten polymer into a mold or forming device in manufacturing processes...
|
|
WO/2006/123726 |
A pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) vitamin D or a vitamin D derivative or a pharmacologically acceptable salt thereof; a therapeutic a...
|
|
WO/2006/124899 |
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...
|
|
WO/2006/124899 |
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...
|
|
WO/2006/121095 |
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...
|
|
WO/2006/120755 |
Provided is a process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid more efficiently and industrially advantageously. The process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid repre...
|
|
WO/2006/117611 |
The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1 -4 alkylene and B a C3-4...
|
|
WO/2006/116158 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of...
|
|
WO/2006/114432 |
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...
|
|
WO/2006/114432 |
The invention pertains to a method for purifying glycolide comprising the step of distilling crude glycolide under reflux using a distillation column having a ratio S/CxL > 1.1 and S2/C2L > 0.4 m, wherein S stands for the inner surface o...
|
|
WO/2006/110221 |
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...
|
|
WO/2006/106241 |
The invention relates to a compound of formula (I) in which: R1, R2, R3, R4, while being identical or different, each represent an atom or group selected among H, halogen, alkyl, alkoxy, phenyl and cyano; X represents a bond, an oxygen a...
|
|
WO/2006/103527 |
The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical...
|
|
WO/2006/102760 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
|
|
WO/2006/098308 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/095020 |
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.
|
|
WO/2006/092623 |
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group -(CH2)...
|
|
WO/2006/085108 |
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...
|
|
WO/2006/081276 |
Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.
|
|
WO/2006/081332 |
The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower...
|
|
WO/2006/072189 |
Described are substituted spiro[bornyl-2,4'-(1,3-dioxanes)], a method for their production and fragrance compositions comprising them.
|
|
WO/2006/072189 |
Described are substituted spiro[bornyl-2,4'-(1,3-dioxanes)], a method for their production and fragrance compositions comprising them.
|
|
WO/2006/069656 |
The invention relates to compounds of the formula (I) in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as ...
|
|
WO/2006/067466 |
The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the f...
|
|
WO/2006/067466 |
The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the f...
|
|
WO/2006/064611 |
ABSTRACT Disclosed is a process for purifying a hydroxycarboxylic acid, comprising: a crystallization step of subjecting a hydroxycarboxylic acid aqueous solution to crystallization for purification, a separation step of separating a hyd...
|
|
WO/2006/062093 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/061372 |
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention...
|
|
WO/2006/062110 |
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...
|
|
WO/2006/058648 |
The present invention relates to compounds of Formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and...
|
|
WO/2006/050212 |
The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of...
|
|
WO/2006/048620 |
Liquid crystal compounds of Formula (I) for use in liquid crystal devices contains a dioxatetralin unit within the mesogenic liquid crystal core. The dioxatetralin unit may be located at any position within the mesogenic core of the liqu...
|
|
WO/2006/038606 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/034641 |
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...
|
|
WO/2006/030892 |
The invention aims at providing a process for the production of NS-220 which is suitable for mass production on an industrial scale. The invention is constituted of (1) a process for the production of methyl cis-5-(4-chlorobutyl) -2-meth...
|
|
WO/2006/028972 |
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...
|
|
WO/2006/024627 |
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...
|
|
WO/2006/024627 |
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...
|
